CoChat

Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice

Open access

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Abstract

Background: Yinzhihuang (YZH) oral liquid is a traditional Chinese medicine compound that has emerged as a promising therapeutic agent for non-alcoholic fatty liver disease (NAFLD). Here, we aimed to investigate the therapeutic effects of YZH on non-alcoholic steatohepatitis (NASH) and elucidate its underlying molecular mechanisms. Methods: Mice fed on a high-fat diet plus fructose/glucose drinking water (HFGD) were treated with YZH (30 mL/kg/d). The effects of YZH on mice with NASH were assessed through serological analysis and histological examination. Microbiota analysis based on 16S ribosomal ribonucleic acid (16S rRNA) and intestinal mucosal barrier function, serum inflammatory factors, hepatic macrophage infiltration, as well as hepatic toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor kappa B (NFκB) pathway were carried out to explore the mechanism of YZH for treatment of NASH. Results: Results of the current study found that YZH effectively reduced body weight gain and adiposity and alleviated hepatocyte steatosis, hepatocyte ballooning, liver tissue lobular inflammation, as well as fibrosis. It also reduced the accumulation of triglycerides, cholesterol, and free fatty acids in the liver of the treated mice and normalized serum aspartate transaminase, alanine transaminase, and glucose levels as well as lipid metabolism. Meanwhile, YZH treatment significantly decreased the abundance of harmful bacteria, such as Mucispirillum, Helicobacter , and Desulfovibrionaceae . Mechanistically, the present study found that YZH upregulated the expression of tight junction proteins, decreased serum lipopolysaccharide, interleukin 6, and tumor necrosis factor α levels, and increased interleukin 10 levels in serum. In the liver, YZH alleviated macrophage infiltration, especially that of pro-inflammatory macrophages. Moreover, it was found that YZH inhibited the canonical TLR4, MyD88, NFκB signaling pathway. Conclusions: In conclusion, YZH may be a new agent for the prevention of NASH. Further, YZH alleviates gut microbiota dysbiosis, restores the intestinal mucosal barrier, and inhibits the canonical TLR4, MyD88, NFκB signaling pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21037/atm-21-4809

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Yinzhihuang (YZH) reduced body weight, liver weight, and fat weight of mice fed with high-fat diet plus fructose/glucose drinking water (HFGD). C57/BL6J mice were divided into 3 groups: the control group was given normal food and drinking water and was given an equal volume of normal saline by gavage (ND group); the model group was given high-fat food and high-sugar water and was given an equal volume of normal saline by gavage (HFGD group); the treatment group was given high-fat food and high-sugar water and 30 mL/kg/d YZH by gavage (HFGD + Y group). (A) Changes in body weight of mice in each group with feeding time; (B) weight gain of mice in each group compared with initial body weight; (C) daily food intake of mice in each group; (D) representative gross image of liver and inguinal fat of mice in each group; (E) comparison of the liver weight of mice; (F) comparison of the inguinal fat weight of mice. N=6. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Figure 1 Yinzhihuang (YZH) reduced body weight, liver weight, and fat weight of mice fed with high-fat diet plus fructose/glucose drinking water (HFGD). C57/BL6J mice were divided into 3 groups: the control group was given normal food and drinking water and was given an equal volume of normal saline by gavage (ND group); the model group was given high-fat food and high-sugar water and was given an equal volume of normal saline by gavage (HFGD group); the treatment group was given high-fat food and high-sugar water and 30 mL/kg/d YZH by gavage (HFGD + Y group). (A) Changes in body weight of mice in each group with feeding time; (B) weight gain of mice in each group compared with initial body weight; (C) daily food intake of mice in each group; (D) representative gross image of liver and inguinal fat of mice in each group; (E) comparison of the liver weight of mice; (F) comparison of the inguinal fat weight of mice. N=6. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.CC BY-NC-ND · PubMed Central
Figure 2 Yinzhihuang (YZH) decreased steatosis activity fibrosis (SAF) score and the volume of inguinal fat cells in non-alcoholic steatohepatitis (NASH) mice. (A) The representative photograph of hematoxylin and eosin (H&E) staining, Oil red O and Sirius red staining of liver paraffin section, together with H&E staining of inguinal adipose tissue paraffin section; the arrows in the liver H&E staining indicated the lobular inflammation area, and the arrows in the Sirius red staining indicated the collagen deposition area. (B) The evaluation of liver steatosis based on H&E staining; (C) the evaluation of liver steatosis based on Oil red O; (D) hydroxyproline content in the liver tissues of the 3 groups of mice; (E) the evaluation of the relative inguinal fat area based on H&E staining; (F) SAF score of each group. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
Figure 2 Yinzhihuang (YZH) decreased steatosis activity fibrosis (SAF) score and the volume of inguinal fat cells in non-alcoholic steatohepatitis (NASH) mice. (A) The representative photograph of hematoxylin and eosin (H&E) staining, Oil red O and Sirius red staining of liver paraffin section, together with H&E staining of inguinal adipose tissue paraffin section; the arrows in the liver H&E staining indicated the lobular inflammation area, and the arrows in the Sirius red staining indicated the collagen deposition area. (B) The evaluation of liver steatosis based on H&E staining; (C) the evaluation of liver steatosis based on Oil red O; (D) hydroxyproline content in the liver tissues of the 3 groups of mice; (E) the evaluation of the relative inguinal fat area based on H&E staining; (F) SAF score of each group. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.CC BY-NC-ND · PubMed Central
Figure 3 Yinzhihuang (YZH) reduced liver lipid accumulation and serum aminotransferase levels in non-alcoholic steatohepatitis (NASH) mice. (A) Liver triglycerides content in each group; (B) liver cholesterol content in each group; (C) liver free fatty acid content in each group; (D) serum aspartate aminotransferase level of 3 groups of mice; (E) serum alanine aminotransferase level of 3 groups of mice. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ****P<0.0001.
Figure 3 Yinzhihuang (YZH) reduced liver lipid accumulation and serum aminotransferase levels in non-alcoholic steatohepatitis (NASH) mice. (A) Liver triglycerides content in each group; (B) liver cholesterol content in each group; (C) liver free fatty acid content in each group; (D) serum aspartate aminotransferase level of 3 groups of mice; (E) serum alanine aminotransferase level of 3 groups of mice. Data were expressed as mean ± SD. *P<0.05, **P<0.01, ****P<0.0001.CC BY-NC-ND · PubMed Central
Figure 4 Yinzhihuang (YZH) improved glucolipid metabolic disorders in non-alcoholic steatohepatitis (NASH) mice. (A) Serum triglyceride content in each group; (B) serum total cholesterol content in each group; (C) fasting blood glucose levels in each group; (D) fasting blood insulin levels in each group; (E) insulin resistance index in each group; (F) intraperitoneal glucose tolerance test in 3 groups of mice; (G) insulin tolerance test in 3 groups of mice. Data were shown as mean ± SD. ND vs. high-fat diet plus fructose/glucose drinking water (HFGD), *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; HFGD vs. HFGD + Y, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001.
Figure 4 Yinzhihuang (YZH) improved glucolipid metabolic disorders in non-alcoholic steatohepatitis (NASH) mice. (A) Serum triglyceride content in each group; (B) serum total cholesterol content in each group; (C) fasting blood glucose levels in each group; (D) fasting blood insulin levels in each group; (E) insulin resistance index in each group; (F) intraperitoneal glucose tolerance test in 3 groups of mice; (G) insulin tolerance test in 3 groups of mice. Data were shown as mean ± SD. ND vs. high-fat diet plus fructose/glucose drinking water (HFGD), *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; HFGD vs. HFGD + Y, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001.CC BY-NC-ND · PubMed Central
Figure 5 YZH regulated the composition of intestinal flora. (A) Principal component analysis (PCA) of the 3 groups; (B) principal coordinate analysis (PCoA) of the 3 groups; (C) differences in the phylum level of the intestinal flora of the 3 groups of mice; (D) differences in the ratio of Firmicutes/Bacteroidetes in the 3 groups of mice; (E) differences in the genus level of the intestinal flora of the 3 groups of mice. Data were shown as mean ± SD. *P<0.05; **P<0.01. YZH, yinzhihuang.
Figure 5 YZH regulated the composition of intestinal flora. (A) Principal component analysis (PCA) of the 3 groups; (B) principal coordinate analysis (PCoA) of the 3 groups; (C) differences in the phylum level of the intestinal flora of the 3 groups of mice; (D) differences in the ratio of Firmicutes/Bacteroidetes in the 3 groups of mice; (E) differences in the genus level of the intestinal flora of the 3 groups of mice. Data were shown as mean ± SD. *P<0.05; **P<0.01. YZH, yinzhihuang.CC BY-NC-ND · PubMed Central
Figure 6 YZH protected the intestinal mucosal barrier and reduced endotoxemia. (A) Serum LPS levels in the 3 groups of mice; (B) Spearman correlation analysis between Desulfovibrio and blood LPS; (C) Serum FITC-Dextran levels in the 3 groups of mice; (D) representative electron micrographs of the terminal ileum of the 3 groups of mice. The upper images indicated the degree of edema of the intestinal microvilli; the middle images indicated the shortness of the intestinal microvilli; the lower images indicated the decrease of the mitochondrial cristae. Red arrows indicated typical parts. (E) The protein levels of ZO-1, occludin, and claudin-1 were evaluated by immunohistochemistry; (F) serum IL-6 levels in each group; (G) serum TNF-α levels in each group; (H) serum IL-10 levels in each group. Data were shown as mean ± SD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. YZH, yinzhihuang; LPS, lipopolysaccharide; ZO-1, zonula occludens 1; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; IL-10, interleukin-10 .
Figure 6 YZH protected the intestinal mucosal barrier and reduced endotoxemia. (A) Serum LPS levels in the 3 groups of mice; (B) Spearman correlation analysis between Desulfovibrio and blood LPS; (C) Serum FITC-Dextran levels in the 3 groups of mice; (D) representative electron micrographs of the terminal ileum of the 3 groups of mice. The upper images indicated the degree of edema of the intestinal microvilli; the middle images indicated the shortness of the intestinal microvilli; the lower images indicated the decrease of the mitochondrial cristae. Red arrows indicated typical parts. (E) The protein levels of ZO-1, occludin, and claudin-1 were evaluated by immunohistochemistry; (F) serum IL-6 levels in each group; (G) serum TNF-α levels in each group; (H) serum IL-10 levels in each group. Data were shown as mean ± SD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. YZH, yinzhihuang; LPS, lipopolysaccharide; ZO-1, zonula occludens 1; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; IL-10, interleukin-10 .CC BY-NC-ND · PubMed Central
Figure 7 YZH decreased pro-inflammatory macrophages and relieved liver inflammation. (A) The expression of F4/80 in liver was evaluated by immunohistochemistry; (B) the statistics of F4/80 positive cells in each group; (C) the expression of IRF5 in liver was evaluated by IHC; (D) the statistics of IRF5 positive cells in each group; (E) the expression of monocyte MCP-1 at the mRNA level of the 3 groups of mice; (F) the expression of IL-1β at the mRNA level of the 3 groups of mice. Data were shown as mean ± SD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. YZH, yinzhihuang; IRF5, interferon regulatory factor 5; IHC, immunohistochemistry; MCP-1, chemoattractant protein 1; mRNA, ribosomal ribonucleic acid; IL-1β, interleukin-1 beta.
Figure 7 YZH decreased pro-inflammatory macrophages and relieved liver inflammation. (A) The expression of F4/80 in liver was evaluated by immunohistochemistry; (B) the statistics of F4/80 positive cells in each group; (C) the expression of IRF5 in liver was evaluated by IHC; (D) the statistics of IRF5 positive cells in each group; (E) the expression of monocyte MCP-1 at the mRNA level of the 3 groups of mice; (F) the expression of IL-1β at the mRNA level of the 3 groups of mice. Data were shown as mean ± SD. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. YZH, yinzhihuang; IRF5, interferon regulatory factor 5; IHC, immunohistochemistry; MCP-1, chemoattractant protein 1; mRNA, ribosomal ribonucleic acid; IL-1β, interleukin-1 beta.CC BY-NC-ND · PubMed Central
Figure 8 YZH attenuated NASH by inhibiting the hepatic TLR4, MyD88, NFκB pathway. (A) The expressions of TLR4, MyD88, IκBα, p-IκBα, NFκB and p-NFκB in the liver tissues of the 3 groups of mice were detected by Western Blot; (B) protein levels of TLR4, MyD88, IκBα, p-IκBα, NFκB and p-NFκB in 3 groups were calculated. Data were shown as mean ± SD. **P<0.01; ****P<0.0001. YZH, yinzhihuang; NASH, non-alcoholic steatohepatitis; TLR4, toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NFκB, nuclear factor kappa B; IκBα, inhibitor of NFκB alpha.
Figure 8 YZH attenuated NASH by inhibiting the hepatic TLR4, MyD88, NFκB pathway. (A) The expressions of TLR4, MyD88, IκBα, p-IκBα, NFκB and p-NFκB in the liver tissues of the 3 groups of mice were detected by Western Blot; (B) protein levels of TLR4, MyD88, IκBα, p-IκBα, NFκB and p-NFκB in 3 groups were calculated. Data were shown as mean ± SD. **P<0.01; ****P<0.0001. YZH, yinzhihuang; NASH, non-alcoholic steatohepatitis; TLR4, toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NFκB, nuclear factor kappa B; IκBα, inhibitor of NFκB alpha.CC BY-NC-ND · PubMed Central
Figure 9 Graphic abstract. Yinzhihuang oral liquid effectively alleviated steatosis, inflammation, and fibrosis, reduced serum aspartate transaminase and alanine transaminase, and improved glycolipid metabolism of NASH mouse. Meanwhile, YZH treatment significantly decreased the abundance of harmful bacteria, such as Mucispirillum, Helicobacter, and Desulfovibrionaceae. Mechanistically, YZH reduced gut leaky, decreased serum LPS, IL-6, and TNF-α levels, and increased IL10 in serum. In the liver, YZH decreased MCP-1, IL-1β and alleviated macrophage infiltration, especially pro-inflammatory macrophages. Moreover, YZH inhibited the canonical TLR4, MyD88, NFκB signaling pathway. NASH, non-alcoholic steatohepatitis; YZH, yinzhihuang; LPS, lipopolysaccharide; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; MCP-1, monocyte chemoattractant protein 1; IL-1β, interleukin-1 beta; TLR4, toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NFκB, nuclear factor kappa B.
Figure 9 Graphic abstract. Yinzhihuang oral liquid effectively alleviated steatosis, inflammation, and fibrosis, reduced serum aspartate transaminase and alanine transaminase, and improved glycolipid metabolism of NASH mouse. Meanwhile, YZH treatment significantly decreased the abundance of harmful bacteria, such as Mucispirillum, Helicobacter, and Desulfovibrionaceae. Mechanistically, YZH reduced gut leaky, decreased serum LPS, IL-6, and TNF-α levels, and increased IL10 in serum. In the liver, YZH decreased MCP-1, IL-1β and alleviated macrophage infiltration, especially pro-inflammatory macrophages. Moreover, YZH inhibited the canonical TLR4, MyD88, NFκB signaling pathway. NASH, non-alcoholic steatohepatitis; YZH, yinzhihuang; LPS, lipopolysaccharide; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha; MCP-1, monocyte chemoattractant protein 1; IL-1β, interleukin-1 beta; TLR4, toll-like receptor 4; MyD88, myeloid differentiation primary response 88; NFκB, nuclear factor kappa B.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 10

Metadata

Authors
Li, S., Chen, F., Zou, Y., Ning, L., Zhang, G., Zhang, S., & Yao, Q.
Affiliations
Fudan University (CN)
Corresponding author
  • Zhang, Shuncai
  • Yao, Qunyan
Venue
Annals of Translational Medicine
Published
2022-06
Volume
10
Issue
11
Pages
631-631
ISSN
  • 2305-5839 (ISSN-L)
  • 2305-5847
OpenAlex
W4285026031
Cited by
10
References
72
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2
FWCI
1.26
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Annals of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (82000575, 81500460)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
nonalcoholic steatohepatitis, gut-liver axis, gut dysbiosis, intestinal barrier, TLR4/MyD88/NF-κB signaling, steatosis, liver fibrosis, traditional Chinese medicine, high-fat fructose diet, lipopolysaccharide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice. https://app.cochat.ai/papers/10.21037/atm-21-4809
The paper
Li, S., Chen, F., Zou, Y., Ning, L., Zhang, G., Zhang, S., & Yao, Q. (2022). Yinzhihuang oral liquid protects against non-alcoholic steatohepatitis via modulation of the gut-liver axis in mice. Annals of Translational Medicine. https://doi.org/10.21037/atm-21-4809

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.